Item 1.01 | Entry into a Material Definitive Agreement. |
Put Option Agreement, Securities Purchase Agreement and Warranty Agreement
On December 14, 2020, Trinseo S.A., a public limited liability company (société anonyme) existing under the laws of Luxembourg (the “Company”) entered into a Put Option Agreement (the “Put Option Agreement”), with Arkema S.A., a company organized under the laws of France (the “Seller”), relating to the transfer of the business of developing, manufacturing, regenerating and selling activated methyl methacrylates (MMA) and polymethyl methacrylates (PMMA) (the “Business,” as further defined therein) currently operated by certain of subsidiaries of the Seller. Appended to the Put Option Agreement are: (i) a form of securities purchase agreement (the “SPA”) and (ii) a form of warranty agreement relating thereto (the “Warranty Agreement” and, together with the SPA, the “Transaction Documents”) (the transaction being referred to as the “Acquisition”). Together the Transaction Documents provide for the Acquisition at an initial purchase price of EUR 1,137,000,000, subject to customary working capital and other closing adjustments as set forth in the SPA, payable at closing of the transactions.
Under the Put Option Agreement, following completion of the consultation processes with the Works Councils (as defined in the SPA), the Company irrevocably undertook to execute and deliver the Transaction Documents (together with their respective annexes, schedules or appendixes) concurrently with the execution and delivery by the Seller on the date and location set forth in the put option exercise notice. In consideration for the Company’s undertakings under the Put Option Agreement, the Seller granted the Company an exclusivity undertaking for a duration of one year.
If the Put Option is exercised by the Seller, under the SPA, the Seller would make certain fundamental representations and warranties as to the organization and the ownership of the target Business and agrees to indemnify the Company, subject to certain exceptions and limitations set forth in the SPA, in connection with any Specific Liabilities defined therein, subject to certain deductions and exceptions and agreed indemnity caps. In addition, if the Put Option is exercised by the Seller, under the Warranty Agreement, the Seller would make additional representations and warranties regarding the target Business subject to the indemnity limitations set forth in the Warranty Agreement. In addition, as part of the Acquisition, the Company has obtained a warranty and indemnity insurance policy which will provide coverage for certain breaches of the representations and warranties of the Seller in the SPA and Warranty Agreement, in each case subject to a retention amount, exclusions, policy limits and certain other terms and conditions.
The parties’ obligations to complete the transaction under the SPA will be subject to the absence of a Material Adverse Change (as defined in the SPA) having occurred before September 1, 2021, or any subsequent date mutually agreed in writing between the Company and the Seller, the completion of certain pre-closing reorganizations, the receipt of certain antitrust clearances, as well as certain other customary conditions and approvals. The Seller’s put option under the Put Option Agreement can be exercised and is irrevocable until the Put Option Expiry Time (as defined in the Put Option Agreement). The closing is expected to occur by mid-2021.
The foregoing description of the Transaction Documents is only a summary, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Transaction Documents, which are attached as Exhibit 2.1 to this report and incorporated by reference herein. The Transaction Documents and the above description have been included to provide investors and security holders with information regarding the terms of the Transaction Documents. They are not intended to